BVD-523 (Ulixertinib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BVD-523 (Ulixertinib), covering 2018-09-05 to 2018-09-05. Get the full timeline:
Most recent: Clinical Trial Update: Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes [Phase 1, Phase 2]